Wall Street is navigating uncertainty due to ongoing updates about Iran and the Strait of Hormuz, while research suggests a recovery could boost stocks. The market has seen upward earnings revisions, and investors are advised to target companies with strong momentum, particularly those ranked Zacks #1 (Strong Buy).
One stock highlighted for its growth potential is Phibro Animal Health Corporation (PAHC), which has seen a 330% increase in stock price over the past two years, including a 46% rise year-to-date. PAHC is projected to achieve 15% revenue growth in FY26, reaching $1.54 billion, with adjusted earnings expected to increase by 45% in FY26.
Currently trading at a 15% discount to its medical sector and a 38% discount to its highs, PAHC shows strong fundamentals, making it an attractive option for investors seeking value and growth.
